Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 10/2018

01-10-2018 | Breast Oncology

Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast

Authors: Amita A. Desai, MD, Rafael E. Jimenez, MD, Tanya L. Hoskin, MS, Courtney N. Day, BS, Judy C. Boughey, MD, Tina J. Hieken, MD

Published in: Annals of Surgical Oncology | Issue 10/2018

Login to get access

Abstract

Background

Pleomorphic lobular carcinoma in situ (PLCIS) is an uncommon high-grade in situ lesion that shares morphologic features of both classic lobular and ductal carcinoma in situ. Data on the natural history of pure PLCIS are limited, and no evidence-based consensus guidelines for management exist.

Methods

From our prospectively maintained institutional pathology and breast surgery databases, we identified all patients with a diagnosis of PLCIS on core needle biopsy (CNB) or excisional biopsy from 2004 to 2017. Patient, tumor, treatment, and outcome data were abstracted to analyze upstage rates and treatment outcomes.

Results

We identified 18 patients with pure PLCIS: 15 diagnosed on CNB, 2 diagnosed at operation for atypia on CNB, and 1 diagnosed after excisional biopsy without preceding CNB. Of the 15 patients with PLCIS on CNB, 3 (20%) were upgraded to invasive cancer on surgical excision. Overall, 7 patients were treated with mastectomy (all margin-negative) and 11 with lumpectomy (one with a focally positive margin). Eight patients received adjuvant therapy: six endocrine therapy, one radiation therapy, and one received both. Among patients with a final diagnosis of PLCIS, two ipsilateral recurrences were observed at follow-up: one invasive lobular carcinoma at 87 months and one PLCIS at 16 months postoperatively.

Conclusion

PLCIS on CNB mandates surgical resection as 20% of patients may be upgraded to invasive cancer, and outcomes following pathologic margin-negative surgical resection were excellent with only one invasive recurrence observed. Larger-scale investigation with longer follow-up is needed to define a role for adjuvant therapy and to develop evidence-based treatment guidelines.
Literature
1.
Frost AR, Tsangaris TN, Silverberg SG. Pleomorphic lobular carcinoma in situ. Pathol Case Rev. 1996;1:27–31.CrossRef
2.
Gomes DS, Porto SS, Rocha RM, Gobbi H. Usefulness and limitations of E-cadherin and beta-catenin in the classification of breast carcinomas in situ with mixed pattern. Diagn Pathol. 2013;8:114.CrossRefPubMedPubMedCentral
3.
Masannat YA, Baines SK, Pinder SE, Purushotham AD. Challenges in the management of pleomorphic lobular carcinoma in situ of the breast. Breast. 2013;22(2):194–6.CrossRefPubMed
4.
NCCN Clinical Practice Guidelines in Oncology. Breast Cancer 2018. Accessed 30 Mar 2018; Available at www.​NCCN.​org.
5.
Pieri AJ, Harvey J, Bundred N. Pleomorphic lobular carcinoma in situ of the breast: can the evidence guide practice? World J Clin Oncol. 2014;5:546–53.CrossRefPubMedPubMedCentral
6.
Blair SL, Emerson DK, Kulkarni S, Hwang ES, Malcarne V, Ollila DW. Breast surgeon’s survey: no consensus for surgical treatment of pleomorphic lobular carcinoma in situ. Breast J. 2013;19:116–8.CrossRefPubMed
7.
Blair SL, Thompson K, Rococco J, Malcarne V, Beitsch PD, Ollila DW. Attaining negative margins in breast-conservation operations: is there a consensus among breast surgeons? J Am Coll Surg. 2009;209:608–13.CrossRefPubMed
8.
Sullivan ME, Khan SA, Sullu Y, Schiller C, Susnik B. Lobular carcinoma in situ variants in breast cores: potential for misdiagnosis, upgrade rates at surgical excision, and practical implications. Arch Pathol Lab Med. 2010;134:1024–8.PubMed
9.
Khoury T, Karabakhtsian RG, Mattson D, et al. Pleomorphic lobular carcinoma in situ of the breast: clinicopathological review of 47 cases. Histopathology. 2014;64:981–93.CrossRefPubMedPubMedCentral
10.
Chen YY, Hwang ES, Roy R, et al. Genetic and phenotypic characteristics of pleomorphic lobular carcinoma in situ of the breast. Am J Surg Pathol. 2009;33: 1683–94.CrossRefPubMedPubMedCentral
11.
12.
De Brot M, Koslow MS, Muhsen S, et al. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat. 2017;165:411–420.CrossRefPubMedPubMedCentral
13.
Downs-Kelly E, Bell D, Perkins GH, Sneige N, Middleton LP. Clinical implications of margin involvement by pleomorphic lobular carcinoma in situ. Arch Pathol Lab Med. 2011;135:737–43.PubMed
14.
15.
Fasola CE, Chen JJ, Jensen KC, Allison KH, Horst KC. Characteristics and clinical outcomes of pleomorphic lobular carcinoma in situ of the breast. Breast J. 2018;4:66–69.CrossRef
16.
Flanagan MR, Rendi MH, Calhoun KE, Anderson BO, Javid SH. Pleomorphic lobular carcinoma in situ: radiologic-pathologic features and clinical management. Ann Surg Oncol. 2015;22:4263–9.CrossRefPubMedPubMedCentral
17.
Gradishar WJ, Anderson BO, Balassanian R, et al. Breast cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:310–320.CrossRefPubMed
18.
Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999;353:1993–2000.CrossRefPubMed
19.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–88.CrossRefPubMed
Metadata
Title
Treatment Outcomes for Pleomorphic Lobular Carcinoma In Situ of the Breast
Authors
Amita A. Desai, MD
Rafael E. Jimenez, MD
Tanya L. Hoskin, MS
Courtney N. Day, BS
Judy C. Boughey, MD
Tina J. Hieken, MD
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 10/2018
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-018-6591-6

Other articles of this Issue 10/2018

Annals of Surgical Oncology 10/2018 Go to the issue

Breast Oncology

Breast Cancer Litigation in the 21st Century

Breast Oncology

Triple Mapping to Optimize Axillary Management in Breast Cancer Patients After Neoadjuvant Therapy

Breast Oncology

‘Driving’ Rates Down: A Population-Based Study of Opening New Radiation Therapy Centers on the Use of Mastectomy for Breast Cancer

Breast Oncology

Satisfaction and Sustainability in a Surgical Career

Breast Oncology

Timing and Delays in Breast Cancer Evaluation and Treatment

Breast Oncology

Chronic Pain After Breast Surgery: A Prospective, Observational Study